Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on Monday that its experimental drug, when combined with Novo Nordisk ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Telehealth platform Hims & Hers is set to acquire UK startup Zava to strengthen its international presence. Meanwhile, ...